Key result
Lower end-tidal CO2 was associated with shorter survival in patients with pulmonary arterial hypertension.
Why the study?
Does lower end-tidal CO2 correlate with worse long-term survival in patients with pulmonary arterial hypertension?
Cohort (n=82)
No
Does lower end-tidal CO2 correlate with worse long-term survival in patients with pulmonary arterial hypertension?
Lower end-tidal CO2 measured noninvasively at the bedside is associated with shorter long-term survival in patients with pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Does not support routine use in pulmonary arterial hypertension; hypothesis-generating and requires prospective validation.
Rationale Pulmonary arterial hypertension (PAH) is characterized in part by increased dead space ventilation, which can be estimated noninvasively at the bedside by measurement of end-tidal CO2 (ETco2). Objectives Prior work has demonstrated that ETco2 is lower in patients with PAH than in control patients, but whether ETco2 has prognostic value is unknown. We hypothesized that lower measurements of ETco2 in patients with PAH correlate with worse long-term outcomes. Methods Patients with PAH seen in our referral clinic were prospectively recruited for ETco2 measurement between September 2009 and February 2010. Vital status as of July 2015 was documented using medical records and the Social Security Death Index. Results Eighty-two patients were followed for a median of 60 months. Twenty-six patients died, and two were lost to follow-up. Patients who died were more likely to be older (58.5 ± 14.9 vs. 47.6 ± 12.2 yr; P < 0.05) and to have shorter 6-minute walk distance (296 ± 127 vs. 401 ± 92 m; P < 0.05). Mean ETco2 in survivors was 30.5 ± 4.8 mm Hg, whereas mean ETco2 in patients who died was 27.1 ± 4.2 mm Hg (P = 0.004). After stratification by median baseline ETco2 of 29 mm Hg, survival in each group was analyzed. Patients with lower ETco2 had shorter survival (P = 0.006). Cox regression analysis with ETco2 as a continuous variable revealed the hazard ratio to be 0.88 (95% confidence interval, 0.80–0.97; P = 0.006). In 52 patients with more than one measurement a median of 17 months apart, ETco2 was unchanged. Conclusions Our single-center data suggest that lower ETco2 is associated with shorter survival and that ETco2 is stable over time in patients with PAH.
No takes yet. Share an insight, caveat, or question.
Welch et al. (2017) conducted a cohort in Pulmonary arterial hypertension (n=82). End-tidal CO2 (ETco2) measurement vs. Higher vs lower ETco2 was evaluated on Survival (HR 0.88, 95% CI 0.80-0.97, p=0.006). Lower end-tidal CO2 was associated with shorter survival in patients with pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: